{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/CORT/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T11:59:00.173Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9133,"canonical_name":"CORCEPT THERAPEUTICS INC","cik":"0001088856","uei":null,"lei":null,"duns":null,"ticker":"CORT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":86,"clinical":9,"open":1},"count":96,"timeline":[{"ts":"2026-09-17","kind":"sec.insider.17493","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":17493,"price_per_share":8.27,"usd_value":144667,"security_title":"Common Stock","importance":15.14466711},{"ts":"2026-09-16","kind":"sec.insider.296","reporter":"Vieira Roberto Wandenkolk","title":"President, Oncology","shares":296,"price_per_share":100.82,"usd_value":29843,"security_title":"Common Stock","importance":15.02984272},{"ts":"2026-07-17","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-07-17","url_slug":"/sec/cik-0001088856/4/0001193125-26-308058","accession_number":"0001193125-26-308058","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-07-17","url_slug":"/sec/cik-0001088856/4/0001193125-26-308061","accession_number":"0001193125-26-308061","importance":30},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":28460,"price_per_share":87.8863,"usd_value":2501244,"security_title":"Common Stock","importance":37.501244098},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":7919,"price_per_share":86.776,"usd_value":687179,"security_title":"Common Stock","importance":35.687179144},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":3969,"price_per_share":87.7356,"usd_value":348223,"security_title":"Common Stock","importance":35.3482225964},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":3520,"price_per_share":88.3016,"usd_value":310822,"security_title":"Common Stock","importance":35.310821632},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":2974,"price_per_share":88.8105,"usd_value":264122,"security_title":"Common Stock","importance":35.264122427},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":1978,"price_per_share":89.4881,"usd_value":177007,"security_title":"Common Stock","importance":35.1770074618},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":1079,"price_per_share":86.7777,"usd_value":93633,"security_title":"Common Stock","importance":35.0936331383},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":101,"price_per_share":89.4282,"usd_value":9032,"security_title":"Common Stock","importance":35.0090322482},{"ts":"2026-07-15","kind":"sec.insider.m","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":24167,"price_per_share":23.06,"usd_value":557291,"security_title":"Common Stock","importance":15.55729102},{"ts":"2026-07-15","kind":"sec.insider.m","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":15833,"price_per_share":19.26,"usd_value":304944,"security_title":"Common Stock","importance":15.30494358},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-07-08","url_slug":"/sec/cik-0001088856/4/0001193125-26-298865","accession_number":"0001193125-26-298865","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-07-08","url_slug":"/sec/cik-0001088856/4/0001193125-26-298871","accession_number":"0001193125-26-298871","importance":30},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Guyer William","title":"Officer","shares":20000,"usd_value":1862530,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001973251-26-000028","importance":40.372506},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Guyer William","title":"Chief Development Officer","shares":19048,"price_per_share":93.1059,"usd_value":1773481,"security_title":"Common Stock","importance":36.7734811832},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Guyer William","title":"Chief Development Officer","shares":952,"price_per_share":93.5383,"usd_value":89048,"security_title":"Common Stock","importance":35.0890484616},{"ts":"2026-07-07","kind":"sec.filing","form_type":"144","title":"144 — CORCEPT THERAPEUTICS INC — 2026-07-07","url_slug":"/sec/cik-0001088856/144/0001973251-26-000028","accession_number":"0001973251-26-000028","importance":30},{"ts":"2026-07-07","kind":"sec.insider.19048","reporter":"Guyer William","title":"Chief Development Officer","shares":19048,"price_per_share":93.1059,"usd_value":1773481,"security_title":"Common Stock","importance":16.7734811832},{"ts":"2026-07-07","kind":"sec.insider.20000","reporter":"Guyer William","title":"Chief Development Officer","shares":20000,"price_per_share":21.65,"usd_value":433000,"security_title":"Common Stock","importance":15.433},{"ts":"2026-07-07","kind":"sec.insider.m","reporter":"Guyer William","title":"Chief Development Officer","shares":20000,"price_per_share":21.65,"usd_value":433000,"security_title":"Common Stock","importance":15.433},{"ts":"2026-07-07","kind":"sec.insider.952","reporter":"Guyer William","title":"Chief Development Officer","shares":952,"price_per_share":93.5383,"usd_value":89048,"security_title":"Common Stock","importance":15.0890484616},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-07-06","url_slug":"/sec/cik-0001088856/4/0001193125-26-296296","accession_number":"0001193125-26-296296","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Maduck Sean","title":"See Remarks","shares":11175,"price_per_share":89.3094,"usd_value":998033,"security_title":"Common Stock","importance":35.998032545},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Maduck Sean","title":"See Remarks","shares":11024,"price_per_share":87.3349,"usd_value":962780,"security_title":"Common Stock","importance":35.9627799376},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Maduck Sean","title":"See Remarks","shares":2801,"price_per_share":88.5127,"usd_value":247924,"security_title":"Common Stock","importance":35.2479240727},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Maduck Sean","title":"See Remarks","shares":25000,"price_per_share":8.27,"usd_value":206750,"security_title":"Common Stock","importance":15.20675},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-18","url_slug":"/sec/cik-0001088856/4/0001193125-26-275963","accession_number":"0001193125-26-275963","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-18","url_slug":"/sec/cik-0001088856/4/0001193125-26-275964","accession_number":"0001193125-26-275964","importance":30},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"MAHONEY DAVID L","title":null,"shares":20000,"price_per_share":84.5253,"usd_value":1690506,"security_title":"Common Stock","importance":36.690506},{"ts":"2026-06-17","kind":"sec.filing","form_type":"8-K","title":"8-K — CORCEPT THERAPEUTICS INC — 2026-06-17","url_slug":"/sec/cik-0001088856/8-k/0001193125-26-274258","accession_number":"0001193125-26-274258","importance":35},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-17","url_slug":"/sec/cik-0001088856/4/0001193125-26-274224","accession_number":"0001193125-26-274224","importance":30},{"ts":"2026-06-16","kind":"sec.form144","reporter":"WILSON JAMES N","title":"Director","shares":30000,"usd_value":2496147,"security_title":"COMMON","approx_sale_date":"2026-06-16","accession_number":"0001949846-26-000385","importance":40.4992294},{"ts":"2026-06-16","kind":"sec.form144","reporter":"MAHONEY DAVID L","title":"Director","shares":20000,"usd_value":1666800,"security_title":"Common","approx_sale_date":"2026-06-16","accession_number":"0001949846-26-000386","importance":40.33336},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":5823,"price_per_share":83.5708,"usd_value":486633,"security_title":"Common Stock","importance":35.4866327684},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"WILSON JAMES N","title":null,"shares":4177,"price_per_share":82.6948,"usd_value":345416,"security_title":"Common Stock","importance":35.3454161796},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":19483,"price_per_share":81.8092,"usd_value":1593889,"security_title":"Common Stock","importance":36.5938886436},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":11081,"price_per_share":80.9424,"usd_value":896923,"security_title":"Common Stock","importance":35.8969227344},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":9434,"price_per_share":80.0216,"usd_value":754924,"security_title":"Common Stock","importance":35.7549237744},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":2,"price_per_share":82.45,"usd_value":165,"security_title":"Common Stock","importance":35.0001649},{"ts":"2026-06-15","kind":"sec.insider.m","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":40000,"price_per_share":19.26,"usd_value":770400,"security_title":"Common Stock","importance":15.7704},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-04","url_slug":"/sec/cik-0001088856/4/0001193125-26-257618","accession_number":"0001193125-26-257618","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/8-k/0001193125-26-254622","accession_number":"0001193125-26-254622","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/4/0001193125-26-256002","accession_number":"0001193125-26-256002","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/4/0001193125-26-256011","accession_number":"0001193125-26-256011","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/4/0001193125-26-256013","accession_number":"0001193125-26-256013","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/4/0001193125-26-256015","accession_number":"0001193125-26-256015","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-06-03","url_slug":"/sec/cik-0001088856/4/0001193125-26-256022","accession_number":"0001193125-26-256022","importance":30},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Guyer William","title":"Chief Development Officer","shares":20000,"price_per_share":70.6,"usd_value":1412000,"security_title":"Common Stock","importance":36.412},{"ts":"2026-06-02","kind":"sec.insider.m","reporter":"Guyer William","title":"Chief Development Officer","shares":20000,"price_per_share":21.65,"usd_value":433000,"security_title":"Common Stock","importance":15.433},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Maduck Sean","title":"See Remarks","shares":452,"price_per_share":70.44,"usd_value":31839,"security_title":"Common Stock","importance":15.03183888},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":395,"price_per_share":70.44,"usd_value":27824,"security_title":"Common Stock","importance":15.0278238},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":358,"price_per_share":70.44,"usd_value":25218,"security_title":"Common Stock","importance":15.02521752},{"ts":"2026-06-02","kind":"sec.insider.f","reporter":"Lyon Joseph Douglas","title":"See Remarks","shares":269,"price_per_share":70.44,"usd_value":18948,"security_title":"Common Stock","importance":15.01894836},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Mokari Atabak","title":"Officer","shares":160000,"usd_value":11200016,"security_title":"Common Stock","approx_sale_date":"2026-06-01","accession_number":"0001972481-26-000177","importance":42.2400032},{"ts":"2026-06-01","kind":"sec.form144","reporter":"BELANOFF JOSEPH K","title":"Officer","shares":12837,"usd_value":892043,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001973251-26-000018","importance":40.1784086},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":40000,"price_per_share":70.0001,"usd_value":2800004,"security_title":"Common Stock","importance":37.800004},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Maduck Sean","title":"See Remarks","shares":21069,"price_per_share":70.1068,"usd_value":1477080,"security_title":"Common Stock","importance":36.4770801692},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"BELANOFF JOSEPH K","title":"Chief Executive Officer","shares":12837,"price_per_share":69.74,"usd_value":895252,"security_title":"Common Stock","importance":35.89525238},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Maduck Sean","title":"See Remarks","shares":3931,"price_per_share":70.7462,"usd_value":278103,"security_title":"Common Stock","importance":35.2781033122},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — CORCEPT THERAPEUTICS INC — 2026-06-01","url_slug":"/sec/cik-0001088856/144/0001972481-26-000177","accession_number":"0001972481-26-000177","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — CORCEPT THERAPEUTICS INC — 2026-06-01","url_slug":"/sec/cik-0001088856/144/0001973251-26-000018","accession_number":"0001973251-26-000018","importance":30},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":40000,"price_per_share":19.26,"usd_value":770400,"security_title":"Common Stock","importance":15.7704},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Maduck Sean","title":"See Remarks","shares":25000,"price_per_share":8.27,"usd_value":206750,"security_title":"Common Stock","importance":15.20675},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Guyer William","title":"Chief Development Officer","shares":877,"price_per_share":70.44,"usd_value":61776,"security_title":"Common Stock","importance":15.06177588},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":776,"price_per_share":70.44,"usd_value":54661,"security_title":"Common Stock","importance":15.05466144},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":634,"price_per_share":70.44,"usd_value":44659,"security_title":"Common Stock","importance":15.04465896},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Maduck Sean","title":"See Remarks","shares":615,"price_per_share":70.44,"usd_value":43321,"security_title":"Common Stock","importance":15.0433206},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Lyon Joseph Douglas","title":"See Remarks","shares":537,"price_per_share":70.44,"usd_value":37826,"security_title":"Common Stock","importance":15.03782628},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":776,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Mokari Atabak","title":"Chief Financial Officer","shares":634,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Maduck Sean","title":"See Remarks","shares":615,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Guyer William","title":"Chief Development Officer","shares":877,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.insider.a","reporter":"Lyon Joseph Douglas","title":"See Remarks","shares":537,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-29","kind":"sec.insider.g","reporter":"BELANOFF JOSEPH K","title":"Chief Executive Officer","shares":300000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-29","kind":"sec.insider.g","reporter":"BELANOFF JOSEPH K","title":"Chief Executive Officer","shares":150000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-29","kind":"sec.insider.g","reporter":"BELANOFF JOSEPH K","title":"Chief Executive Officer","shares":150000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-27","kind":"sec.insider.g","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.form144","reporter":"Lyon Joseph Douglas","title":"Officer","shares":5000,"usd_value":291100,"security_title":"Common","approx_sale_date":"2026-05-20","accession_number":"0001959173-26-003811","importance":40.05822},{"ts":"2026-05-20","kind":"sec.filing","form_type":"144","title":"144 — CORCEPT THERAPEUTICS INC — 2026-05-20","url_slug":"/sec/cik-0001088856/144/0001959173-26-003811","accession_number":"0001959173-26-003811","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer","security_title":"PHASE1,PHASE2","status":"TERMINATED","accession_number":"NCT03437941","excerpt":"The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study.","importance":80},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — CORCEPT THERAPEUTICS INC — 2026-05-15","url_slug":"/sec/cik-0001088856/4/0001193125-26-227411","accession_number":"0001193125-26-227411","importance":30},{"ts":"2026-05-13","kind":"sec.insider.g","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":5300,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.g","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":1000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.g","reporter":"Robb Gary Charles","title":"Chief Business Officer","shares":1000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06108219","excerpt":"[\"Nonalcoholic Steatohepatitis (NASH)\",\"Metabolic Dysfunction-associated Steatohepatitis (MASH)\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Evaluating the Pharmacokinetics and Safety of Miricorilant","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07553663","excerpt":"[\"Nonalcoholic Steatohepatitis (NASH)\",\"Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis\",\"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)\",\"Non-alcoholic Fatty Liver Disease (NAFLD)\"]","importance":30},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07259317","excerpt":"[\"Adenocarcinoma\",\"Carcinoma, Pancreatic Ductal\"]","importance":45},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03604198","excerpt":"[\"Cushing Syndrome\"]","importance":45},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06906341","excerpt":"[\"Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Peritoneal Neoplasms\",\"Endometrial Cancer\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07240116","excerpt":"[\"Healthy\"]","importance":30},{"ts":"2026-04-03","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07276373","excerpt":"[\"Neoplasms\"]","importance":45},{"ts":"2026-03-30","kind":"clinical.trial","reporter":"Corcept Therapeutics","title":"Dazucorilant in Patients With Amyotrophic Lateral Sclerosis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT05407324","excerpt":"[\"Amyotrophic Lateral Sclerosis\"]","importance":45},{"ts":"2024-12-31","kind":"open.payments","reporter":"Corcept Therapeutics","title":"$3832871.0 to 11455 physicians (2024–2024)","security_title":"manufacturer","excerpt":"Korlym","accession_number":"2024","usd_value":3832871,"importance":70}]}